U.S. Markets closed

Entasis Therapeutics Holdings Inc. (ETTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0600+0.0100 (+0.49%)
At close: 4:00PM EDT

Entasis Therapeutics Holdings Inc.

35 Gatehouse Drive
Waltham, MA 02451
United States
781 810 0120

Full Time Employees47

Key Executives

NameTitlePayExercisedYear Born
Dr. Manoussos PerrosPres, CEO & Director751.44kN/A1968
Dr. Michael J. GutchCFO, Chief Bus. Officer & Sec.482.94kN/A1966
Dr. Ruben TommasiChief Scientific OfficerN/AN/A1966
Ms. Elizabeth M. KeileyGen. CounselN/AN/A1966
Ms. Colleen TuckerHead of HRN/AN/AN/A
Dr. John Patrick Mueller Ph.D.Chief Devel. OfficerN/AN/A1960
Dr. David AltaracChief Medical OfficerN/AN/A1961
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Entasis Therapeutics Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.